北京商报讯(记者丁宁)1月22日晚间,针对吸收合并及私有化复宏汉霖事项未获复宏汉霖股东大会通过这一事项,复星医药(600196)方面向北京商报记者表示,对复宏汉霖私有化议案未能通过表示遗憾,也充分尊重所有股东的决定,复星医药将一如既往地支持复宏汉霖长期健康发展。 复星医药表示,公司坚持创新驱动,围绕未被满足的临床需求,重点强化抗体/ADC、细胞治疗、小分子等核心技术平台,将坚定支持复宏汉霖这一...
Source Link北京商报讯(记者丁宁)1月22日晚间,针对吸收合并及私有化复宏汉霖事项未获复宏汉霖股东大会通过这一事项,复星医药(600196)方面向北京商报记者表示,对复宏汉霖私有化议案未能通过表示遗憾,也充分尊重所有股东的决定,复星医药将一如既往地支持复宏汉霖长期健康发展。 复星医药表示,公司坚持创新驱动,围绕未被满足的临床需求,重点强化抗体/ADC、细胞治疗、小分子等核心技术平台,将坚定支持复宏汉霖这一...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.